Lv61
1800 积分 2022-08-12 加入
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
2天前
已完结
Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia
5天前
已关闭
Iptacopan in IgA Nephropathy — Final 24-Month Data
13天前
已完结
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
17天前
已完结
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
25天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
1个月前
已完结
Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease
1个月前
已完结
Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN
1个月前
已完结
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
1个月前
已完结
皖公网安备34019202002308
